A Phase I/II Safety, Tolerability, and 'Proof of Concept' Study of TNFerade Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer.

Trial Profile

A Phase I/II Safety, Tolerability, and 'Proof of Concept' Study of TNFerade Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Golnerminogene pradenovec (Primary) ; Fluorouracil; Hydroxycarbamide
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TNF-CORE
  • Sponsors GenVec
  • Most Recent Events

    • 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jun 2008 Encouraging interim data presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top